Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) generates frequent news flow around its efforts to develop and commercialize therapies for endocrine diseases and endocrine-related tumors. Company announcements highlight progress across its GPCR-targeted small-molecule portfolio, including regulatory milestones, clinical trial updates, capital markets activity, and corporate developments.
News coverage often focuses on PALSONIFY™ (paltusotine), Crinetics’ once-daily, oral somatostatin receptor type 2 agonist. Updates have included U.S. FDA approval for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option, early launch metrics, and the design and enrollment status of the pivotal Phase 3 CAREFNDR trial in carcinoid syndrome associated with neuroendocrine tumors.
Investors and observers can also follow regular announcements on atumelnant, the company’s investigational ACTH receptor antagonist in late-stage development for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. Press releases describe Phase 2 results, the CALM-CAH Phase 3 trial design, biomarker changes such as reductions in androstenedione, and safety observations from both core studies and open-label extensions.
Additional news items cover the advancement of CRN09682, a nonpeptide drug conjugate targeting SST2-expressing tumors, including first-patient dosing in the Phase 1/2 BRAVESST2 trial and details of the trial’s dose-escalation and expansion phases. Crinetics also reports on preclinical programs like CRN12755 and CRN10329 through R&D Day presentations and conference abstracts.
Beyond R&D, Crinetics issues releases on public offerings of common stock, inducement equity grants under its 2021 Employment Inducement Incentive Award Plan, participation in major healthcare conferences, and executive transitions disclosed via Form 8-K. For users tracking CRNX, this news page provides a centralized view of the company’s clinical, regulatory, financial, and corporate announcements over time.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced that on January 10, 2026 its Compensation Committee granted inducement equity awards to 10 new non-executive employees under the 2021 Inducement Plan.
The grants consist of 37,575 non-qualified stock options and 25,525 restricted stock units (RSUs). Options have an exercise price of $53.25, equal to the Jan. 9, 2026 closing price. Options vest over four years with 25% at the one-year anniversary and the remainder in 36 equal monthly installments; RSUs vest in four equal annual installments, each subject to continued employment.
The awards were made as inducements material to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the 2021 Inducement Plan and applicable award agreements.
Crinetics Pharmaceuticals (Nasdaq: CRNX) priced an underwritten public offering of 7,620,000 common shares at $45.95 per share, generating gross proceeds of approximately $350 million. The underwriters have a 30-day option to purchase an additional 1,143,000 shares. The offering is expected to close on or about January 8, 2026, subject to customary closing conditions.
Crinetics intends to use net proceeds, together with existing cash and investments, to fund the commercial launch of PALSONIFY, research and development of product candidates, other research programs, general corporate purposes, and potentially in-license or acquire complementary assets, although no commitments currently exist. Joint bookrunning managers include Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler, and Cantor; Baird is lead manager.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced on January 5, 2026 its intent to sell $350.0 million of common stock in an underwritten public offering, with a 30-day underwriter option to purchase up to an additional $52.5 million of shares. All shares will be sold by the company and the offering is subject to market and other conditions with no assurance of completion.
Crinetics intends to use net proceeds, together with existing cash and investments, to fund the PALSONIFY™ commercial launch, R&D, other research programs, general corporate purposes, and potentially in-license or acquire complementary assets; it has no current commitments to do so. Joint bookrunners include Leerink, J.P. Morgan, Evercore ISI, Piper Sandler, and Cantor. The offering is being made from an effective shelf registration; a prospectus supplement will be filed with the SEC.
Crinetics (Nasdaq: CRNX) reported unaudited PALSONIFY U.S. net product revenue of >$5 million for Q4 2025 and early commercial traction with >200 enrollment forms and >125 unique prescribers as of Dec 31, 2025.
In Phase 2 TouCAHn cohort 4, atumelnant 80 mg produced a mean 67% reduction in morning androstenedione (A4) at week 12 and enabled 88% of completers to reduce glucocorticoid doses to physiologic levels; no hepatic transaminase adverse events were observed.
Crinetics Pharmaceuticals (Nasdaq: CRNX) will host a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide a PALSONIFY (paltusotine) commercialization update and to disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia (CAH).
The event includes prepared remarks followed by a live Q&A. A live audio-only webcast will be available and an archived webcast will be posted on the company's Events & Presentations page at www.crinetics.com/events. Dial-in numbers: 1-833-470-1428 (U.S.) or 1-646-844-6383 (international); Access Code: 640078.
Crinetics Pharmaceuticals (NASDAQ: CRNX) announced that Scott Struthers, Ph.D., Founder and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 9:45 a.m. Pacific Time.
The announcement notes an audio-only live webcast will be available and an archived webcast will be posted on the company’s Events & Presentations page at www.crinetics.com/events. Investors seeking 1×1 meetings should contact their conference representative.
Crinetics (Nasdaq: CRNX) announced dosing of the first patient in the CALM-CAH Phase 3 trial of atumelnant on December 11, 2025. The randomized, placebo-controlled adult study will evaluate atumelnant’s ability to reduce excess adrenal androgens and lower glucocorticoid use while assessing other clinical outcomes that reflect disease control.
Atumelnant is described as the first-and-only small-molecule ACTH receptor antagonist in late-stage clinical development for classic congenital adrenal hyperplasia (CAH). Phase 2 data showed rapid, sustained reductions in biomarkers including androstenedione and 17-hydroxyprogesterone, plus clinical measures such as adrenal size and resumption of menses. Atumelnant has also received FDA Orphan Drug designation for classic CAH.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced on December 10, 2025 inducement equity awards under its 2021 Inducement Plan to nine new non-executive employees.
The Compensation Committee granted an aggregate of 39,575 non-qualified stock options and 26,525 restricted stock units (RSUs). Options have an exercise price of $48.06, equal to the Dec. 10, 2025 closing price. Options vest over four years (25% at one year, then monthly over 36 months); RSUs vest in four equal annual installments, all subject to continued employment and plan terms. Grants were made pursuant to Nasdaq Listing Rule 5635(c)(4).
Crinetics (Nasdaq: CRNX) announced the first patient has been dosed in the Phase 1/2 BRAVESST2 trial evaluating CRN09682 for metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing tumors on Dec 3, 2025.
CRN09682 is the lead candidate from Crinetics’ proprietary nonpeptide drug conjugate (NDC) platform, designed for selective SST2 binding, rapid receptor internalization, and intratumoral release of a cytotoxic payload. The first-in-human, open-label study will assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity across dose-escalation and dose-expansion phases, enrolling up to 150 participants with SST2 confirmation by somatostatin receptor imaging.
Crinetics (Nasdaq: CRNX) announced the first patient randomized in the pivotal Phase 3 CAREFNDR trial of once-daily oral paltusotine for adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors on Nov 20, 2025.
The randomized, double-blind, placebo-controlled study will enroll 141 adults randomized 2:1 to paltusotine 80 mg or placebo; the primary endpoint is change in flushing episodes/day from baseline to Week 12 and a key secondary is change in bowel movements/day. The trial includes a 16-week randomized period followed by a 104-week open-label extension that will evaluate long-term efficacy, safety and monitor progression-free survival. Global enrollment is expected through 2025–2026.
FAQ
What is the current stock price of Crinetics Pharmaceuticals (CRNX)?
What is the market cap of Crinetics Pharmaceuticals (CRNX)?
